Page last updated: 2024-12-08

rotundifolone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rotundifolone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID442497
CHEBI ID8900
SCHEMBL ID2317471
MeSH IDM0442088

Synonyms (26)

Synonym
piperitenone oxide
3564-96-3
rotundifolone
C09896
lippione
(1s,6s)-6-methyl-3-propan-2-ylidene-7-oxabicyclo[4.1.0]heptan-2-one
6fr5iod112 ,
piperitenone oxide, (+-)-
cis-piperitenone epoxide
7-oxabicyclo(4.1.0)heptan-2-one, 6-methyl-3-(1-methylethylidene)-, (1s)-
unii-6fr5iod112
(+-)-rotundifolone
piperitenone oxide [fhfi]
fema no. 4199
7-oxabicyclo(4.1.0)heptan-2-one, 6-methyl-3-(1-methylethylidene)-, (1s,6s)-
(+-)-piperitenone oxide
(+)-piperitenone oxide
piperitenone oxide, (+)-
(+)-rotundifolone
SCHEMBL2317471
CHEBI:8900
Q27108176
DTXSID301317536
HY-134013
CS-0136507
AKOS040753565

Research Excerpts

Actions

ExcerptReferenceRelevance
"Rotundifolone elicits an increase in the current density of BK(Ca) channels and causes a shift in the steady-state inactivation relationship for Ca(v) type-L towards more hyperpolarized membrane potentials."( Rotundifolone-induced relaxation is mediated by BK(Ca) channel activation and Ca(v) channel inactivation.
Albuquerque, JG; Araújo, DA; Araújo, IG; Barbosa-Filho, JM; Cavalcante, KV; Correia, NA; Cruz, JS; De Medeiros, IA; Dias, KL; Nunes, XP; Porto, DL; Silva, DF; Veras, RC, 2011
)
2.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oxacycleAny organic heterocyclic compound containing at least one ring oxygen atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's7 (77.78)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.15 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index5.00 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]